Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Lung cancer doctors eye Keytruda over Opdivo

Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.

Read More »

Hong Kong confirms first case of Zika virus

Hong Kong has confirmed its first case of Zika, putting the Asian financial center on high alert for any spread of the mosquito-borne virus that has wreaked havoc in Latin America, the Caribbean and beyond.

Read More »

Mylan offers discounts on EpiPen after criticism

Mylan NV said it would reduce the out-of-pocket cost of its severe allergy treatment EpiPen through a discount program after lawmakers criticized the drug’s high price.

Read More »

Led by Former Genentech Execs, Denali Banks $130 Million, Initiates Trial and Announces a Handful of Partnerships

Denali Therapeutics announced a broad range of news, including the start of a Phase I trial in Alzheimer’s disease, a number of collaborations and licensing deals, and a $130 million Series B financing round.

Read More »

Job Cuts Loom as Takeda to Shutter Cambridge Office and Quits the UK

After a nine-year presence in the area, Takeda is beginning to wind down its operations in Cambridge, U.K., as the company undergoes a refocusing of its research and development activities that will favor Japan and the United States.

Read More »

Amgen Remains Hush-Hush Over FDA Rejection of Parsabiv

Thousand Oaks, Calif.-based Amgen’s Parsabiv (etelcalcetide) for secondary hyperparathyroidism was rejected by the U.S. Food and Drug Administration, but the company has held off on why or any other details.

Read More »

Novartis: Positive Phase III results for MS drug

Novartis AG said a late-stage study showed its oral once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.

Read More »

Biomerica Approved for Listing on the Nasdaq Capital Market

  Company to Begin Trading on Nasdaq on August 26, 2016: Shares Will Trade as BMRA   IRVINE, CA–(Marketwired – August 24, 2016) – Biomerica Inc. (OTCQB: BMRA) today announced that its common stock has been approved for listing on the Nasdaq Capital Market and is expected to commence trading on Nasdaq under the ticker […]

Read More »

Regular nut nibbling linked to low inflammation

Eating a handful of nuts five times per week may reduce inflammation, a condition that contributes to heart disease, diabetes and many other chronic illnesses, say the authors of a recent U.S. study.

Read More »

Pfizer to buy AstraZeneca’s antibiotics business

Pharmaceutical company AstraZeneca has agreed to sell its small molecule antibiotics business to Pfizer Inc. in a deal that could be valued at more than $1.5 billion.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom